Nina Trentmann is the former bureau chief for The Wall Street Journal’s CFO Journal. Based in New York, Nina managed the ...

While Alnylam has not released an official statement regarding the financial impact of the CHMP’s recommendation, investors have responded favorably to the news. The stock’s upward movement reflects ...

The EMA’s Committee for Medicinal Products for Human Use adopted a positive opinion, recommending a change to the terms of the marketing ...

Drugmakers breathed a sigh of relief Wednesday after President Trump didn’t announce pharmaceutical tariffs. Plus, language in the executive order indicated medicines were exempted from the ...

Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price target of ...

Over the last 7 days, the United States market has experienced a 1.7% drop, but it has shown resilience with a 3.6% rise over the past year and an anticipated annual earnings growth of 13%. In this ...

FDA Commissioner Marty Makary talks about his plans to revamp drug development and reduce ‘conflicts of interest’ between the ...

Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis ...

According to Benzinga Pro, Alnylam Pharmaceuticals's peer group average for short interest as a percentage of float is 5.87%, ...